Evaluate Use of Mangosteen Juice Added to Usual Care in Reducing Risk of Recurrent Atrial Fibrillation

NCT ID: NCT00951301

Last Updated: 2016-03-16

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 143 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-07-31
• Study Completion Date: 2013-06-30

Brief Summary

This study is being done to see if the addition of mangosteen juice to standard medical care will reduce the risk of atrial fibrillation (AF) recurrence following direct current (DC) cardioversion. The study will also look at the effects the mangosteen juice may have on biomarkers of inflammation and endothelial cell dysfunction (the tissue lining the arteries does not function properly).

Detailed Description

Mangosteen Effects on Inflammatory Markers in Atrial Fibrillation Trial is a study designed to test the primary hypothesis that a dietary supplement (Mangosteen) containing anti-inflammatory and anti-oxidant properties may effect the measured levels of inflammatory biomarkers. Secondarily, this study will compare the attenuation of markers of endothelial cell dysfunction including endothelial progenitor cells (EPCs), clinical levels of anticoagulation (INR), digoxin, lipids, and glycosylated hemoglobin (Hgb A1c), quality of life measurements, AF recurrences, and associated levels of inflammatory markers with those experiencing recurrent AF between the mangosteen group and the placebo group.

This trial will randomize 250 patients presenting to the Mayo Clinic Cardioversion Unit over one year to two groups including a mangosteen supplemented group versus a control group with placebo juice. Patients will be enrolled who have a history of paroxysmal, persistent, or longstanding persistent atrial fibrillation and excluded if they have a history of recent surgery, myocardial infarction, infection, collagen vascular disease with active inflammation, or thyroid disease. Furthermore, patients already on corticosteroids will be excluded. Patients will be evaluated at enrollment and followed at 3 months and 6 months with repeat ECG, laboratory testing of inflammatory biomarkers and endothelial function, as well as quality of life questions.

The trial will track the effect of natural juices containing anti-inflammatory and anti-oxidant properties on inflammatory markers, endothelial progenitor cells, and quality of life. This trial will attempt to determine if any dietary supplement effects to inflammatory markers correlate with the rate of recurrent AF in each of the two groups.

Conditions

Atrial Fibrillation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

mangosteen juice

subjects randomized 1:1 to this arm will receive juice containing the mangosteen ingredient

Group Type: ACTIVE_COMPARATOR

mangosteen juice

Intervention Type: DRUG

6 ounces of juice containing mangosteen taken twice daily, AM and PM, for 6 months duration of study participation.

placebo juice

subjects randomized 1:1 to this arm will receive specially prepared juice not containing mangosteen ingredient

Group Type: PLACEBO_COMPARATOR

placebo juice

Intervention Type: DRUG

6 ounces of specially prepared juice not containing mangosteen taken twice daily, AM and PM, for 6 months duration of the study participation.

Interventions

mangosteen juice

6 ounces of juice containing mangosteen taken twice daily, AM and PM, for 6 months duration of study participation.

Intervention Type: DRUG

placebo juice

6 ounces of specially prepared juice not containing mangosteen taken twice daily, AM and PM, for 6 months duration of the study participation.

Intervention Type: DRUG

Other Intervention Names

Xango juice

Eligibility Criteria

Inclusion Criteria

• Candidates for this study must meet all of the following criteria:

• Age >18 years
• Documented atrial fibrillation with a clinically indicated cardioversion.
• Anticoagulation with therapeutic INR or PTT as per Mayo Clinic cardioversion guidelines.
• Provision of written informed consent.

Exclusion Criteria

• Subjects will be excluded if any of the following conditions apply:

• Presence of atrial fibrillation secondary to a reversible cause such as thyrotoxicosis or alcohol use
• Myocardial infarction within 1 month, CABG or cardiac surgery including surgical maze or AF radiofrequency ablation within the past 3 months
• Presence of an implanted pacemaker, atrial defibrillator, or ventricular defibrillator
• History of bleeding diathesis or coagulopathy
• Known atrial thrombus or contra-indication to cardioversion
• Active infection or collagen vascular disease with active inflammation
• Current use of corticosteroids
• Gastrointestinal (GI) or genitourinary bleed within the past six months requiring transfusion
• Concomitant medical illness (i.e., cancer, congestive heart failure) that may preclude protocol compliance, confound data interpretation or limit life-expectancy to less than one year
• Known allergy to juice components
• Inability or refusal to cooperate with study procedures
• Unsuccessful cardioversion

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Mayo Clinic

OTHER

Sponsor Role: lead

Responsible Party

Brent A. Bauer

PI

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Brent A Bauer, MD

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Mayo Clinic

Rochester, Minnesota, United States

Countries

United States

Other Identifiers

07-007749

Identifier Type: -

Identifier Source: org_study_id